These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24050792)

  • 1. Can the results of the European Randomized Study of Screening for Prostate Cancer be decontaminated?
    Metcalfe C
    Eur Urol; 2014 Feb; 65(2):337-8; discussion 338-9. PubMed ID: 24050792
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.
    Schlomm T
    Eur Urol; 2015 Aug; 68(2):214-5. PubMed ID: 25680240
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Taneja SS
    J Urol; 2015 Aug; 194(2):393-4. PubMed ID: 26195364
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
    Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
    Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial.
    Shoag J; Halpern J; Eisner B; Lee R; Mittal S; Barbieri CE; Shoag D
    JAMA Oncol; 2015 Oct; 1(7):984-6. PubMed ID: 26291583
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 9. Healing or harming: the prostate cancer dichotomy.
    Zarrabi A; Mark S
    N Z Med J; 2020 Oct; 133(1523):12-15. PubMed ID: 33032299
    [No Abstract]   [Full Text] [Related]  

  • 10. The pendulum swings back: Screening for prostate cancer in 2018.
    Thompson IM
    Cancer; 2018 Jul; 124(13):2690-2692. PubMed ID: 29786846
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate-specific antigen-based screening for prostate cancer: the irony of it all.
    Carter HB
    Eur Urol; 2013 Nov; 64(5):710-1; discussion 711-2. PubMed ID: 23773555
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
    Luján M; Páez Á
    Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
    [No Abstract]   [Full Text] [Related]  

  • 13. First, do no harm.
    Pimlott N
    Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer options expand beyond the PSA.
    Clin Resour Manag; 2002 May; 3(5):65-8. PubMed ID: 12048767
    [No Abstract]   [Full Text] [Related]  

  • 15. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience?
    Baum M
    Eur Urol; 2013 Oct; 64(4):540-1. PubMed ID: 23768633
    [No Abstract]   [Full Text] [Related]  

  • 17. Toward a smarter prostate cancer screening program.
    Sjoberg DD
    Eur Urol; 2015 Oct; 68(4):598-9. PubMed ID: 24836056
    [No Abstract]   [Full Text] [Related]  

  • 18. Valentine's Day PSA.
    Dasgupta P
    BJU Int; 2014 Feb; 113(2):177. PubMed ID: 24712694
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
    Roobol MJ; Kranse R; Bangma CH; Otto SJ; van der Kwast TH; Bokhorst LP; de Koning HJ; Schröder FH
    Eur Urol; 2013 Oct; 64(4):541-3. PubMed ID: 23816273
    [No Abstract]   [Full Text] [Related]  

  • 20. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.